

## **NHS AYRSHIRE & ARRAN**

## PATIENT GROUP DIRECTION

Name of Medicine :	Paracetamol Suspension 120mg/5mls
Legal Classification :	Pharmacy (P) or General Sales List (GSL)
PGD Ref No :	CP 22 277
Replacing PGD Ref No :	CP 20 277

Effective Date :	8 <sup>th</sup> December 2022
Review Date :	17 <sup>th</sup> December 2024

Professional Group authorised to use PGD on completion and submission of an Approved Practitioner Form:	Community Pharmacist registered as a member of the General Pharmaceutical Council
--	---

PGD prepared/reviewed* by : (*delete as appropriate)			
	Doctor	Pharmacist	Nurse
Name	John Freestone	lain Fulton	Gillian Moffat
Signature	Fiele	au fall	Septet
	16.11.2022	14/11/2022	17/2/23
Date			

Approved on behalf of NHS Ayrshire & Arran	
Chair or vice chair PGD group:	
Name: Jen Pennycook	
Signature:	
Date: 23/02/2023	

Description of Treatment	
Name of medicine : Paracetamo	bl
POM/P/GSL :	P or GSL
Pharmaceutical Form :	Suspension
Strength :	120mg/5mls
Clinical situation for use of this PGD	Prophylaxis of post vaccination fever
Inclusion criteria	Infants under 12 months of age who are receiving primary doses of MenB vaccine at the same time as other routine vaccines.
	Men B vaccine will usually be given with other routine childhood immunisation at age 2 and 4 months.
	Most infants will be greater than two months of age when presenting for first dose however a small number may be under 8 weeks old. These children are included.
Exclusion criteria	<ul> <li>Infants: <ul> <li>12 months of age or over.</li> <li>Receiving MenB vaccine at 12 month booster dose.</li> <li>Infants born at &lt;32 weeks and currently weighing less than 4kg.</li> <li>Known to have hypersensitivity to paracetamol or any ingredient in the product. Check the marketing authorisation holder's summary of product characteristics (SPC) for details of a brand's ingredients.</li> <li>Known to have impaired liver or kidney function.</li> <li>Known to have rare hereditary problems of fructose intolerance, glucose-galactose malabsorption or sucrose-isomaltase insufficiency.</li> </ul> </li> <li>If administering paracetamol: <ul> <li>Known to have taken a paracetamol based analgesic within the previous 4 hours.</li> <li>Known to have taken the maximum recommended daily dose of paracetamol within the previous 24 hours.</li> <li>Non-consent.</li> </ul> </li> </ul>

Dosage :	60mg (2.5ml of 120mg/5ml oral suspension).
	Three doses of paracetamol are required: 60mg (2.5ml of 120mg/5ml) as soon as possible after vaccination with Men B vaccine.
	A second 60mg (2.5ml of 120mg/5ml oral suspension) dose after 4-6 hours.
	A third 60mg (2.5ml of 120mg/5ml oral suspension) dose after a further 4-6 hours.
	Further doses at intervals appropriate to the age of the child may be administered in the period of up to 48 hours post vaccination if pyrexia persists.
	N.B. For non-vaccine related fever the limit of two doses of paracetamol to children 2 to 3 months remains to ensure that fever which may be due to a serious infection in young infants is quickly diagnosed and treated.
Total Dosage:	180mg in 24 hours
Route of Administration :	Oral
Frequency of Administration :	4 -6 hourly
Duration of Treatment :	3 doses over 24 hours initially up to 6 doses over 48 hours.
Total Treatment Quantity :	180mg (7.5ml) in 24 hours 360mg (15ml) in 48 hours
Action if patient is excluded from treatment under this PGD	Advise about risk of fever following vaccination and how to manage this-see patient advice section. Refer to GP.
Interactions	Refer to SPC or online BNF.
Adverse Effects	In the event of severe adverse reaction the parent/carer of the child should be advised to seek medical advice. Adverse effects of paracetamol are rare but
	hypersensitivity or anaphylactic reactions including skin rash may occur. Very rare cases of serious skin reactions have been reported.
	The parent or carer of the child should be informed about the signs of serious skin

	reactions, and use of the paracetamol should be discontinued at the first appearance of skin rash or any other signs of hypersensitivity. Use the Yellow Card system to report adverse drug reactions online at http://yellowcard.mhra.gov.uk.
Follow-up treatment	Contact GP if fever persists as in Advice to patient/carer.
Written/Verbal Advice to be given to patient/carer	<ul> <li>patient/carer.</li> <li>Explain treatment and course of action:</li> <li>The Green Book advises that after the third paracetamol dose some babies may still develop a fever or continue to be febrile. Fever in the 48 hours after vaccination can be managed with paracetamol at home if the infant is otherwise well.</li> <li>If a fever develops parents/carers should keep the infant cool by making sure they don't have too many layers of clothes or blankets, and give them lots of fluids. If the baby is breast-fed, the best fluid to give is breast milk.</li> <li>If the infant remains febrile 48 hours after immunization medical advice should be sought to exclude other causes.</li> <li>Paracetamol may mask a fever due to other underlying causes such as systemic bacterial infection. Parents/carers should not delay in seeking medical advice if they are concerned that their infant is otherwise unwell.</li> <li>Parents/carers should be advised that these dosing recommendations are specific to</li> </ul>
	<ul> <li>paracetamol use in 48 hours post Men B vaccination and the manufactures dosage instructions should be followed at all other times.</li> <li>Do not give more than 4 doses in any 24 hour period (3 doses for infants 1 to 3 months).</li> <li>Leave at least 4 hours between doses.</li> <li>Do not give anything else containing paracetamol while giving this medicine.</li> </ul>

	<ul> <li>The parent/carer should be advised to seek medical advice in the event of an adverse reaction.</li> <li>Pharmacists should advise that:</li> <li>If the infant has received paracetamol containing products within the last four hours before attending for vaccination then they should wait 4-6 hours before administering further doses.</li> <li>The dosing advice on the purchased product and the manufacturers patient information leaflet will differ from the dosing advice recommended post MenB vaccination.</li> <li>Give parent/carer a copy of the relevant patient information leaflet, if appropriate.</li> </ul>
Record required of Supply/Administration	<ul> <li>The following information should be recorded in the PMR</li> <li>Name of preparation</li> <li>Quantity</li> <li>Any directions for use</li> <li>Date of supply</li> </ul>